A176750 Stock Overview
Engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
DuChemBIO Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,510.00 |
| 52 Week High | ₩19,570.00 |
| 52 Week Low | ₩5,050.00 |
| Beta | 0 |
| 11 Month Change | -13.11% |
| 3 Month Change | 1.47% |
| 1 Year Change | 160.50% |
| 33 Year Change | 97.41% |
| 5 Year Change | 36.24% |
| Change since IPO | 37.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| A176750 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -18.7% | 6.1% | -2.8% |
| 1Y | 160.5% | 14.9% | -3.4% |
Return vs Industry: A176750 exceeded the KR Medical Equipment industry which returned 14.9% over the past year.
Return vs Market: A176750 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A176750 volatility | |
|---|---|
| A176750 Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A176750 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A176750's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | n/a | www.duchembio.com |
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease.
DuChemBIO Co.,Ltd. Fundamentals Summary
| A176750 fundamental statistics | |
|---|---|
| Market cap | ₩391.58b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A176750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A176750 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A176750 perform over the long term?
See historical performance and comparison